Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Biogenexis
- Ownership
- Private
- Development stage
- Other
01
Overview
Biogenexis is an emerging biotechnology company focused on developing next-generation therapies for metabolic disorders, including obesity and type 2 diabetes. The company leverages its expertise in incretin biology to design potent and selective agonists targeting the GLP-1 and GIP receptors. Biogenexis aims to improve patient outcomes by creating treatments with enhanced efficacy and better tolerability profiles compared to existing standards of care. Currently, the company's programs are in the pre-clinical stage of development.
- Therapeutic areas
- EndocrinologyMetabolic Disorders
- Modalities
- Small moleculeMonoclonal antibody
- Industry
- Biotech
Beyond the preview
Go deeper on Biogenexis.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Biogenexis.